


Antimicrobial agent-5

| | |
|--------------------|---|
| Cat. No.: | HY-151399 |
| CAS No.: | 2978694-04-9 |
| Molecular Formula: | C ₃₂ H ₄₈ N ₁₆ |
| Molecular Weight: | 656.83 |
| Target: | Bacterial |
| Pathway: | Anti-infection |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | | | | | | | | | | | | | | | | | |
|------------------|--|------------|----------------|----------------|-------------------|------------------|----------|---------|---|------------|--|----------------|-------------|------------------|----------|---------|--|
| Description | Antimicrobial agent-5 is an potent antimicrobial agent, and displays excellent cell selectivity against Gram-negative bacteria and Gram-positive bacteria. Antimicrobial agent-5 blocks the interaction between LPS and CD14/TLR4 receptor, and shows anti-inflammatory activity against LPS-induced inflammation ^[1] . | | | | | | | | | | | | | | | | |
| In Vitro | <p>Antimicrobial agent-5 (compound 9) (0.5-32 µg/mL, 16 h; 1-128 µg/mL; 24 h) shows potent biofilm inhibitory (IC₅₀=2 µg/mL) and eradicating activities (IC₅₀=16 µg/mL) against multidrug-resistant <i>Pseudomonas aeruginosa</i> (MDRPA)^[1].</p> <p>Antimicrobial agent-5 (5 µg/mL, 20 µg/mL; 18 h) inhibits both the release and expression of nitric oxide (NO) and tumor necrosis factor-α (TNF-α) from LPS-stimulated (1 µg/mL) RAW 264.7 cells^[1].</p> <p>Antimicrobial agent-5 exhibits proteolytic resistance and salt/serum stability^[1].</p> <p>Antimicrobial agent-5 (0.5-256 µg/mL; 2 h) exhibits negligible side effects against sheep red blood cells (sRBCs) with hemolytic activity (the minimum hemolytic concentration, MHC) of >256 µg/mL^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td><td>RAW264.7 cells</td></tr> <tr> <td>Concentration:</td><td>5 µg/mL, 20 µg/mL</td></tr> <tr> <td>Incubation Time:</td><td>18 hours</td></tr> <tr> <td>Result:</td><td>Decreased TNF-α release at 20 µg/mL, with inhibition rate of 72.44%. Results reduction in the LPS-stimulated production of NO, with inhibition rate of 31.51%.</td></tr> </table> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td><td><i>E. coli</i> [KCTC 1682], <i>P. aeruginosa</i> [KCTC 1637], <i>S. epidermidis</i> [KCTC 1917], <i>S. aureus</i> [KCTC1621]</td></tr> <tr> <td>Concentration:</td><td>1-128 µg/mL</td></tr> <tr> <td>Incubation Time:</td><td>24 hours</td></tr> <tr> <td>Result:</td><td>Inhibited Gram-negative bacteria and Gram-positive bacteria with IC₅₀ of 6.1 µM (<i>E. coli</i> [KCTC 1682], <i>P. aeruginosa</i> [KCTC 1637], <i>S. epidermidis</i> [KCTC 1917], <i>S. aureus</i> [KCTC1621]), respectively.</td></tr> </table> | Cell Line: | RAW264.7 cells | Concentration: | 5 µg/mL, 20 µg/mL | Incubation Time: | 18 hours | Result: | Decreased TNF-α release at 20 µg/mL, with inhibition rate of 72.44%. Results reduction in the LPS-stimulated production of NO, with inhibition rate of 31.51%. | Cell Line: | <i>E. coli</i> [KCTC 1682], <i>P. aeruginosa</i> [KCTC 1637], <i>S. epidermidis</i> [KCTC 1917], <i>S. aureus</i> [KCTC1621] | Concentration: | 1-128 µg/mL | Incubation Time: | 24 hours | Result: | Inhibited Gram-negative bacteria and Gram-positive bacteria with IC ₅₀ of 6.1 µM (<i>E. coli</i> [KCTC 1682], <i>P. aeruginosa</i> [KCTC 1637], <i>S. epidermidis</i> [KCTC 1917], <i>S. aureus</i> [KCTC1621]), respectively. |
| Cell Line: | RAW264.7 cells | | | | | | | | | | | | | | | | |
| Concentration: | 5 µg/mL, 20 µg/mL | | | | | | | | | | | | | | | | |
| Incubation Time: | 18 hours | | | | | | | | | | | | | | | | |
| Result: | Decreased TNF-α release at 20 µg/mL, with inhibition rate of 72.44%. Results reduction in the LPS-stimulated production of NO, with inhibition rate of 31.51%. | | | | | | | | | | | | | | | | |
| Cell Line: | <i>E. coli</i> [KCTC 1682], <i>P. aeruginosa</i> [KCTC 1637], <i>S. epidermidis</i> [KCTC 1917], <i>S. aureus</i> [KCTC1621] | | | | | | | | | | | | | | | | |
| Concentration: | 1-128 µg/mL | | | | | | | | | | | | | | | | |
| Incubation Time: | 24 hours | | | | | | | | | | | | | | | | |
| Result: | Inhibited Gram-negative bacteria and Gram-positive bacteria with IC ₅₀ of 6.1 µM (<i>E. coli</i> [KCTC 1682], <i>P. aeruginosa</i> [KCTC 1637], <i>S. epidermidis</i> [KCTC 1917], <i>S. aureus</i> [KCTC1621]), respectively. | | | | | | | | | | | | | | | | |

REFERENCES

[1]. Dinesh Kumar S, et al. Cationic, amphipathic small molecules based on a triazine-piperazine-triazine scaffold as a new class of antimicrobial agents. Eur J Med Chem. 2022 Sep 8;243:114747.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA